

Jorge J Nieva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7949679/publications.pdf>

Version: 2024-02-01

144
papers

6,551
citations

94433

37
h-index

64796

79
g-index

147
all docs

147
docs citations

147
times ranked

8610
citing authors

#	ARTICLE	IF	CITATIONS
1	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. <i>British Journal of Cancer</i> , 2022, 126, 514-520.	6.4	19
2	COVID-19 and the acceleration toward remote cancer care. <i>Baylor University Medical Center Proceedings</i> , 2022, 35, 259-260.	0.5	0
3	Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer. <i>Cancers</i> , 2022, 14, 758.	3.7	10
4	Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data. <i>Drugs - Real World Outcomes</i> , 2022, 9, 333-345.	1.6	4
5	Effect of prior therapy on tumor mutational burden in NSCLC. <i>Translational Lung Cancer Research</i> , 2021, 10, 1231-1238.	2.8	2
6	Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9110-9110.	1.6	10
7	<i>STK11</i> / <i>TP53</i> co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9087-9087.	1.6	2
8	First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2502-2502.	1.6	6
9	Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8535-8535.	1.6	6
10	Prognostic impact of XPO1 mutations in metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20533-e20533.	1.6	1
11	A phase 1 trial of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3021-3021.	1.6	0
12	Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21000-e21000.	1.6	0
13	Phase II trial of soluble EphB4-albumin in combination with PD-1 antibody (pembrolizumab) in relapsed/refractory head neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6016-6016.	1.6	2
14	Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer. <i>Journal of Investigative Medicine</i> , 2021, 69, 1281-1286.	1.6	0
15	Blood-Based Multi-Cancer Detection Using a Novel Variant Calling Assay (DEEPGEN TM): Early Clinical Results. <i>Cancers</i> , 2021, 13, 4104.	3.7	9
16	Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2577-2584.	4.1	66
17	Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2021, 160, 92-98.	2.0	3
18	IMPACT OF EXPANDING LUNG CANCER SCREENING GUIDELINES ON THE EARLY DETECTION OF LUNG CANCER IN WOMEN AND MINORITIES. <i>Chest</i> , 2021, 160, A1611-A1612.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen. <i>Oral Oncology</i> , 2021, 123, 105587.	1.5	2
20	Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. <i>Oncotarget</i> , 2021, 12, 2449-2458.	1.8	5
21	Trimodality vs Chemoradiation and Salvage Resection in cN2 Stage IIIA Non-Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2020, 32, 153-159.	0.6	8
22	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 271-282.	10.7	1,034
23	A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 110-119.	1.1	36
24	Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005819.	1.2	23
25	Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. <i>Oral Oncology</i> , 2020, 111, 104928.	1.5	9
26	Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 839-853.	2.1	11
27	3640 Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases. <i>Annals of Oncology</i> , 2020, 31, S397-S398.	1.2	10
28	Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 583-601.	2.1	4
29	A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs. <i>Frontiers in Oncology</i> , 2020, 10, 591.	2.8	22
30	Intravenous 5-fluoro-2-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 979-993.	2.3	13
31	Preanalytical Variables for the Genomic Assessment of the Cellular and Acellular Fractions of the Liquid Biopsy in a Cohort of Breast Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 319-337.	2.8	19
32	Characterization of NRG1 gene fusion events in solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3113-3113.	1.6	5
33	Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9544-9544.	1.6	3
34	Gender disparities in hormone positive lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21552-e21552.	1.6	0
35	Is there a genomic fingerprint of Radon (Rn)-induced lung cancer (LC)? Comparison of genomic alterations in LC specimens from high and low Rn zones.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1572-1572.	1.6	0
36	Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1901-1911.	1.1	127

#	ARTICLE	IF	CITATIONS
37	Patient reported outcomes can improve performance status assessment: a pilot study. Journal of Patient-Reported Outcomes, 2019, 3, 41.	1.9	22
38	Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. Journal of Translational Medicine, 2019, 17, 294.	4.4	45
39	Detection of NRG1 Gene Fusions in Solid Tumors. Clinical Cancer Research, 2019, 25, 4966-4972.	7.0	145
40	Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding. Scientific Reports, 2019, 9, 3214.	3.3	40
41	P1.01-105 US Real-World Management of EGFR-Mutated Advanced NSCLC: Prescribing and Attrition Data from First-To-Second-Line Treatment. Journal of Thoracic Oncology, 2019, 14, S402.	1.1	3
42	P1.01-96 US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment. Journal of Thoracic Oncology, 2019, 14, S398-S399.	1.1	1
43	Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials. Frontiers in Oncology, 2019, 9, 968.	2.8	5
44	A new anion exchange purification method for Cu stable isotopes in blood samples. Analytical and Bioanalytical Chemistry, 2019, 411, 765-776.	3.7	18
45	Radiomics in Pulmonary Lesion Imaging. American Journal of Roentgenology, 2019, 212, 497-504.	2.2	59
46	Tuberculosis following PD-1 blockade for cancer immunotherapy. Science Translational Medicine, 2019, 11, .	12.4	141
47	Impact of prior chemotherapy or radiation therapy on tumor mutation burden in NSCLC.. Journal of Clinical Oncology, 2019, 37, 2627-2627.	1.6	9
48	DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9100-9100.	1.6	8
49	A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS2648-TPS2648.	1.6	5
50	Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer. Oncotarget, 2019, 10, 7016-7030.	1.8	10
51	KRAS-Mutated Lung Cancer. Current Cancer Research, 2019, , 195-216.	0.2	0
52	Abstract P3-01-09: Tracing clonal evolution of circulating tumor cells and cell-free DNA in a metastatic breast cancer patient. , 2019, , .		0
53	Tumor mutational burden (TMB) profile of <i>K-RAS/TP-53</i> co-mutation in metastatic non-small cell lung cancer (m-NSCLC).. Journal of Clinical Oncology, 2019, 37, 2626-2626.	1.6	0
54	Effect of mandatory research biopsy requirements on initiation of clinical trials.. Journal of Clinical Oncology, 2019, 37, e14057-e14057.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Abstract PL01-01: Physicist vs. physician: Digitizing clinical assessment and using it for evidence-based prediction of outcomes. , 2019, , .		0
56	Effect of Blood Collection Tube Type and Time to Processing on the Enumeration and High-Content Characterization of Circulating Tumor Cells Using the High-Definition Single-Cell Assay. Archives of Pathology and Laboratory Medicine, 2018, 142, 198-207.	2.5	36
57	Comparable Survival Between Upfront Tri-Modality Therapy and Definitive Chemoradiation Therapy Requiring Salvage Resection in cN2 Stage IIIA Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e717.	0.8	0
58	MA21.01 Cbl Mutations (mt) as Important Mediators of Oncogenic RTK Signaling in NSCLC. Journal of Thoracic Oncology, 2018, 13, S429.	1.1	0
59	P2.13-10 Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC. Journal of Thoracic Oncology, 2018, 13, S801-S802.	1.1	2
60	Low-dimensional dynamical characterization of human performance of cancer patients using motion data. Clinical Biomechanics, 2018, 56, 61-69.	1.2	5
61	When it comes to genomic analysis of tumours, don't buy in bulk. British Journal of Cancer, 2018, 118, 1281-1282.	6.4	0
62	Incidence of <i>Neuregulin1</i> (<i>NRG1</i>) gene fusions across tumor types.. Journal of Clinical Oncology, 2018, 36, 12084-12084.	1.6	4
63	Objective metrics of patient activity: Use of wearable trackers and patient reported outcomes in predicting unexpected healthcare events in cancer patients undergoing highly emetogenic chemotherapy.. Journal of Clinical Oncology, 2018, 36, 6519-6519.	1.6	0
64	Abstract 2963: Characterization of disease evolution in sequential sampled metastatic breast cancer using liquid biopsy. , 2018, , .		0
65	Abstract 4591: Integration of genomic analysis and assessment of pre-analytic variables in the HD-SCA workflow: A technical validation study. , 2018, , .		0
66	Abstract 4584: High-definition single-cell analysis of liquid and solid biopsies reveals heterogeneity of circulating tumor cells in metastatic colorectal cancer. , 2018, , .		0
67	Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1139-1145.	2.5	63
68	P2.06-011 Phase 2 Study of MM-121 plus Chemotherapy vs. Chemotherapy Alone in Heregulin-Positive, Locally Advanced or Metastatic NSCLC. Journal of Thoracic Oncology, 2017, 12, S1075-S1076.	1.1	0
69	Mining Human Mobility to Quantify Performance Status. , 2017, , .		3
70	MA 07.02 Response to Ensartinib in TKI Na ⁺ ve ALK+ NSCLC Patients. Journal of Thoracic Oncology, 2017, 12, S1826.	1.1	5
71	Development of metastatic brain disease involves progression through lung metastases in <i>EGFR</i> mutated non-small cell lung cancer. Convergent Science Physical Oncology, 2017, 3, 035002.	2.6	5
72	Biophysical technologies for understanding circulating tumor cell biology and metastasis. Translational Lung Cancer Research, 2017, 6, 473-485.	2.8	13

#	ARTICLE	IF	CITATIONS
73	An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma.. Journal of Clinical Oncology, 2017, 35, TPS6092-TPS6092.	1.6	0
74	Serum phosphatidylcholine is lower among breast cancer patients on systemic chemotherapy.. Journal of Clinical Oncology, 2017, 35, e12571-e12571.	1.6	2
75	Abstract 2603: A patient driven cancer database to collect information, analyze data, and predict outcomes. , 2017, , .		0
76	Abstract 4532: Adrenal metastases in lung cancer: Clinical implications of a mathematical model. , 2017, , .		0
77	Abstract 31: The INSPIRE trial: A randomized trial of neoadjuvant and adjuvant therapy with the IRX-2 regimen in patients with newly diagnosed stage II, III, or IVa squamous cell carcinoma of the oral cavity. , 2017, , .		0
78	Development of metastatic brain disease involves progression through lung metastases in mutated non-small cell lung cancer. Convergent Science Physical Oncology, 2017, 3, .	2.6	3
79	A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC). Annals of Oncology, 2016, 27, vi452.	1.2	2
80	A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D). European Journal of Cancer, 2016, 69, S11.	2.8	11
81	A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. Oncologist, 2016, 21, 1163-1164e.	3.7	32
82	PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study. Annals of Oncology, 2016, 27, vi22.	1.2	1
83	A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, TPS9110-TPS9110.	1.6	3
84	Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort.. Journal of Clinical Oncology, 2016, 34, 8524-8524.	1.6	0
85	Abstract 2711: Spatiotemporal progression patterns in metastatic lung cancer treated with bevacizumab. , 2016, , .		0
86	Spatiotemporal progression of metastatic breast cancer: a Markov chain model highlighting the role of early metastatic sites. Npj Breast Cancer, 2015, 1, 15018.	5.2	37
87	Convergent Science Physical Oncology. Convergent Science Physical Oncology, 2015, 1, 010201.	2.6	0
88	Oncolytic viruses: perspectives on clinical development. Current Opinion in Virology, 2015, 13, 55-60.	5.4	19
89	A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncology, 2015, 51, 376-382.	1.5	50
90	Circulating Tumor Microemboli Diagnostics for Patients with Non-“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1111-1119.	1.1	61

#	ARTICLE	IF	CITATIONS
91	Adrenal Metastases in Lung Cancer: Clinical Implications of a Mathematical Model. <i>Journal of Thoracic Oncology</i> , 2014, 9, 442-446.	1.1	23
92	Entropy, complexity and Markov diagrams for random walk cancer models. <i>Scientific Reports</i> , 2014, 4, 7558.	3.3	28
93	SU-E-J-115: Using Markov Chain Modeling to Elucidate Patterns in Breast Cancer Metastasis Over Time and Space. <i>Medical Physics</i> , 2014, 41, 182-182.	3.0	0
94	A Markov chain model of a longitudinal breast cancer data set.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11040-11040.	1.6	0
95	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. <i>Cancer</i> , 2013, 119, 2383-2390.	4.1	45
96	Spreaders and Sponges Define Metastasis in Lung Cancer: A Markov Chain Monte Carlo Mathematical Model. <i>Cancer Research</i> , 2013, 73, 2760-2769.	0.9	82
97	Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2013, 31, 6047-6047.	1.6	3
98	A randomized double-blind phase II study of the Seneca Valley virus (NTX-010) versus placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least four cycles of platinum-based chemotherapy: Alliance (NCCTG) N0923 study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7509-7509.	1.6	5
99	Dynamic changes in circulating tumor cell levels as a prognostic marker in stage IV non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8109-8109.	1.6	1
100	The effects of multidisciplinary clinics on the variability in timeliness of care for lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e17533-e17533.	1.6	2
101	An Observational Study of Circulating Tumor Cells and 18F-FDG PET Uptake in Patients with Treatment-Naive Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e67733.	2.5	32
102	A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites. <i>Oncology</i> , 2012, 82, 315-320.	1.9	17
103	Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. <i>Physical Biology</i> , 2012, 9, 016005.	1.8	120
104	Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. <i>Physical Biology</i> , 2012, 9, 016003.	1.8	252
105	Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their disease. <i>Future Oncology</i> , 2012, 8, 989-998.	2.4	22
106	A Stochastic Markov Chain Model to Describe Lung Cancer Growth and Metastasis. <i>PLoS ONE</i> , 2012, 7, e34637.	2.5	72
107	ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. <i>Lung Cancer</i> , 2012, 77, 421-426.	2.0	56
108	High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. <i>Physical Biology</i> , 2012, 9, 016004.	1.8	96

#	ARTICLE	IF	CITATIONS
109	Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. <i>Physical Biology</i> , 2012, 9, 016001.	1.8	176
110	Abstract 3619: The absence of cleaved caspase-3 in circulating tumor cells detected using a non-enrichment-based assay. , 2012, , .		1
111	Performance of the high-definition circulating tumor cells (HD-CTC) assay in patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e21074-e21074.	1.6	2
112	Abstract 2369: Correlating circulating tumor cells with 18F-FDG positron emission tomography (PET) uptake in patients with treatment naïve non-small cell lung cancer: A pilot study. , 2012, , .		0
113	Correlation of ERCC1 expression on circulating tumor cells with progression-free survival in metastatic non-small cell lung cancer patients treated with platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10574-10574.	1.6	0
114	Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. <i>Nature</i> , 2011, 477, 99-102.	27.8	459
115	Cholesterol Secosterol Aldehydes Induce Amyloidogenesis and Dysfunction of Wild-Type Tumor Protein p53. <i>Chemistry and Biology</i> , 2011, 18, 920-927.	6.0	38
116	Abstract 4151: High definition circulating tumor cells in patients with non-small cell lung cancer. , 2011, , .		0
117	Cytomorphology of Circulating Colorectal Tumor Cells: A Small Case Series. <i>Journal of Oncology</i> , 2010, 2010, 1-7.	1.3	108
118	The ratio of cholesterol 5,6-secosterols formed from ozone and singlet oxygen offers insight into the oxidation of cholesterol in vivo. <i>Chemical Communications</i> , 2009, , 3098.	4.1	29
119	Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 1468-71.	2.5	41
120	Circulating Tumor Cells From Well-Differentiated Lung Adenocarcinoma Retain Cytomorphologic Features of Primary Tumor Type. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 1468-1471.	2.5	71
121	Genetics of hairy cell leukemia. <i>Oncology Reviews</i> , 2008, 1, 189-194.	1.8	0
122	Purification and characterization of sideroblasts from patients with acquired and hereditary sideroblastic anaemia. <i>British Journal of Haematology</i> , 2008, 143, 446-450.	2.5	7
123	Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. <i>Thrombosis Research</i> , 2008, 122, 604-609.	1.7	93
124	Lipid-Derived Aldehydes Accelerate Light Chain Amyloid and Amorphous Aggregation. <i>Biochemistry</i> , 2008, 47, 7695-7705.	2.5	39
125	Understanding hairy cell leukemia genetics. <i>Leukemia and Lymphoma</i> , 2007, 48, 653-654.	1.3	1
126	Case study of the morphologic variation of circulating tumor cells. <i>Human Pathology</i> , 2007, 38, 514-519.	2.0	144

#	ARTICLE	IF	CITATIONS
127	The clinical significance of circulating tissue factor in prostate cancer. <i>Thrombosis and Haemostasis</i> , 2007, 97, 329-330.	3.4	4
128	Significant Activity of Dasatinib in CLL Demonstrated by Ex-Vivo Assay.. <i>Blood</i> , 2007, 110, 4197-4197.	1.4	2
129	Use of optophoresis as an in vitro predictor of cell response to chemotherapy for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 2194-2202.	1.3	6
130	AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP. <i>New England Journal of Medicine</i> , 2006, 355, 1672-1681.	27.0	489
131	Proatherogenic Effects of the Cholesterol Ozonolysis Products, Atheronal-A and Atheronal-B. <i>Biochemistry</i> , 2006, 45, 7162-7170.	2.5	40
132	Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate α -synuclein fibrilization. <i>Nature Chemical Biology</i> , 2006, 2, 249-253.	8.0	312
133	Immunoglobulins can utilize riboflavin (Vitamin B2) to activate the antibody-catalyzed water oxidation pathway. <i>Immunology Letters</i> , 2006, 103, 33-38.	2.5	20
134	High speed detection of circulating tumor cells. <i>Biosensors and Bioelectronics</i> , 2006, 21, 1893-1899.	10.1	167
135	SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. <i>British Journal of Haematology</i> , 2005, 129, 791-794.	2.5	22
136	Long-Term Dosing of AMG 531 Is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2005, 106, 220-220.	1.4	13
137	Measurement of Blood-Borne Tissue Factor Procoagulant Activity in Healthy Individuals and Cancer Patients Using a Novel Assay.. <i>Blood</i> , 2005, 106, 1938-1938.	1.4	7
138	The antibody-catalyzed water oxidation pathway – a new chemical arm to immune defense?. <i>Trends in Biochemical Sciences</i> , 2004, 29, 274-278.	7.5	61
139	Metabolite-initiated protein misfolding may trigger Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 4752-4757.	7.1	204
140	Patterns of Expression of SHP-1 and JAK-2p in Myelodysplastic Syndromes: A Potential New Prognostic Factor.. <i>Blood</i> , 2004, 104, 3430-3430.	1.4	0
141	Evidence for Ozone Formation in Human Atherosclerotic Arteries. <i>Science</i> , 2003, 302, 1053-1056.	12.6	263
142	Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. <i>Blood</i> , 2003, 102, 810-813.	1.4	143
143	Evidence for Antibody-Catalyzed Ozone Formation in Bacterial Killing and Inflammation. <i>Science</i> , 2002, 298, 2195-2199.	12.6	330
144	Injuries in Youth Ice Hockey: A Pilot Surveillance Strategy. <i>Mayo Clinic Proceedings</i> , 1995, 70, 350-356.	3.0	59